Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06642675 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

nTMS for Negative Symptom in Schizophrenia

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated December 5, 2025 (before its estimated February 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Jun 2025 to Feb 2026v8 Show 4 more changesShow less
    • Enrollment target: 32 to 40
    • Study completion date: Jul 2025 to Mar 2026
    • Eligibility criteria shortened, about 7 words
    • Study description expanded, about 33 words
  2. Study description expanded, about 70 wordsv7
  3. Trial status: Active, Not Recruiting to Recruiting
    • Start date: Nov 1, 2024 to Nov 22, 2024
    • Site details revised
    v6
  4. Trial status: Not Yet Recruiting to Active, Not Recruiting
    • Secondary endpoints: 7 to 8
    v5
  5. Start date: Oct 24, 2024 to Nov 1, 2024
    • Secondary endpoints: 6 to 7
    v4
Show 2 earlier versionsHide 2 earlier versions
  1. Start date: Oct 8, 2024 to Oct 24, 2024
    • Secondary endpoints: 5 to 6
    v3
  2. Secondary endpoints: 4 to 5v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This research aims to test the effectiveness of Navigated transcranial magnetic stimulation (nTMS) of left Supramarginal Gyrus for negative symptoms. In this double-blind, randomized controlled trial, patients will be assigned to active iTBS experimental group or sham iTBS group. Treatment will last for 10 days, and data will be collected at baseline, 1 day and 1 month after treatment.
Trial Details
NCT Number NCT06642675
Lead Sponsor Central South University
Conditions
(from sponsor)		 Schizophrenia
Related terms Schizophrenia
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov